IMMUNO-ONCOLOGY XCHANGE
2024
Philadelphia, March 27

Welcome to hubXchange’s Immuno-Oncology Xchange 2024, Philadelphia, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions. 
Discussion topics will cover Immune Biomarkers, Translational Research, Clinical Development, and Tumor Microenvironment (TME).
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: DoubleTree by Hilton Hotel Philadelphia Airport

SNAPSHOTS OF DISCUSSION TOPICS

  • Predictive biomarkers for IO treatment used in clinical practice now and in the future
  • The rise of spatial omics technologies and their potential for new biomarker discovery
  • Translational strategies to develop clinically safe and effective immune cell engagers
  • How to select the right translational screening model to monitor IO agents
  • Early signals of efficacy, biomarkers and confidence in early clinical I/O trials
  • How to maximize clinical success: Patient selection strategies beyond target expression
  • Exploring different cellular modalities
  • TME-targeting combinations – improving efficacy

Full Xchange Agenda

Immune Biomarkers

Time
Titles and Bullets
Facilitator
8:00 – 8:30
Registration 
8:30 – 9:00

Opening Keynote Presentation

9:05 – 10:05

Addressing the tissue limitations with liquid biopsy – are we ready to bring non-invasive tools to the market?

  • What are the biggest challenges in discovery, development and validation of tissue-based predictive biomarkers?
  • Is liquid biopsy an option to address these challenges?
  • How can we, as drug developers, integrate liquid biopsy tools in clinical development?
  • What are the avenues to help us bring non-invasive biomarker tools to the patients?

Raluca is a scientist with over 10 years experience in pharma drug development. Her interest is in predictive biomarkers and ways on getting the right drug to the right patient.

Raluca Budiu-Predoiu
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings/Networking Break
11:10 – 11:20
Morning Refreshments
11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20
Networking Lunch
13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55
1-2-1 Meetings/Networking Break
15:00 – 15:30

Poster Session

15:35 – 16:35

Biomarker identification in blood for improved cancer diagnosis and response monitoring to immune-checkpoint blockade

  • Peripheral blood biomarkers for monitoring response to
  • Immune checkpoint inhibitor treatment (Novel platforms being explored) Case studies from clear cell RCC
  • TME vs Peripheral blood: how to make the connection.

Sai is an Associate Director, Biomarker lead in Translational Medicine Department at Bristol Myers Squibb. He has been at BMS for 2 years, and he leads biomarker strategy development and implementation in late-stage IO clinical studies. In addition he leads with reverse translation efforts to inform early pipeline. Prior this this, he was at Merck for 7 years as a Biomarker lead in the Translational Molecular Biomarkers Department.

Sai Vikram BMS
16:35 – 17:35
Evening Drinks Reception

Partners

Immuno-Oncology Xchange | Philadelphia 2024
Register